"Investigating Investments in Biopharmaceutical R&D."

Carter, Percy H., Ernst Rudolf Berndt, Joseph A. DiMasi, and Mark Trusheim. Nature Reviews: Drug Discovery Vol. 15, No. 10 (2016): 673-674.

"Has the Era of Slow Growth of Prescription Drug Spending Ended?"

Aitken, Murray, Ernst Rudolf Berndt, David M. Cutler, Michael Kleinrock, and Luca Maini. Health Affairs Vol. 35, No. 9 (2016): 1595-1603.

"Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010."

Berndt, Ernst Rudolf, and Pierre Dubois. International Journal of the Economics of Business Vol. 23, No. 2 (2016): 125-147.

"Regional Variation in Physician Adoption of Antipsychotics: Impact on US Medicare Expenditures."

Donohue, Julie M., Sharon-Lise T. Tormand, Marcela Horvitz-Lennon, Aiju Man, Ernst Rudolf Berndt, and Haiden A. Huskamp. Journal of Mental Health Policy and Economics Vol. 19, No. 2 (2016): 67-78.

"The Clinical Benefits, Ethics, and Economics of Stratified Medicine and Companion Diagnostics."

Trusheim, Mark R., and Ernst R. Berndt. Drug Discovery Today Vol. 20, No. 12 (2015): 1439-1450.

"Biosimilar and Biobetter Scenarios for the U.S. and Europe: What Should We Expect?"

Berndt, Ernst R. and Mark R. Trusheim. In Biobetters: Optimizing Protein Therapeutics, edited by Amy Rosenberg and Barthelemy Demeule, 315-360. New York, NY: Springer Science + Business Media, 2015.

Load More